drugset / Trial / NCT00404820

Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis

NCT00404820

Phase 3 Completed 604 enrolled Novartis
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study was to examine the effect of zoledronic acid and alendronate on bone metabolism as measured by biomarkers in postmenopausal women with osteoporosis.

Timeline

Start
2006-10
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alendronic Acid Small molecule 70 mg Oral
Subject Zoledronic acid Other / unclassified 5 mg Intravenous
Background Calcium carbonate Other / unclassified 1200 mg Oral
Background Vitamin D Other / unclassified 800 iu Oral

Indications